| Heading: |
Vorasidenib |
| Question ID: |
1744316 |
| UIN: |
16008 |
| House: |
Commons |
| Date tabled: |
2024-11-25 |
| Asking Member ID: |
5201 |
| Asking Member display name: |
Victoria Collins
|
| Asking Member handle: |
TweetingCollins
|
| Asking Member Twitter reference: |
@TweetingCollins
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether he plans to carry out Vorasidenib trials on patients that have undergone (a) radiotherapy and (b) chemotherapy. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-12-03 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
1506 |
| Answering Member display name: |
Andrew Gwynne
|
| Answering Member handle: |
GwynneMP
|
| Answering Member Twitter reference: |
@GwynneMP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Research is crucial in tackling brain cancer, which is why the Department spends £1.5 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer as one of the largest areas of i... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |